Raymond James' Q2FY25 projected revenue and EPS will be inferior to what it achieved in Q1. Read why RJF stock is revised ...

Hold 20% of your portfolio in cash with SGOV and JAAA to tackle market volatility and recession risks. Reassess after Q1 GDP.

The year 2024 saw Windtree make great progress in many key areas including clinical development of our lead drug candidate istaroxime in cardiogenic shock, business development and the future strategy ...